Concept Architecture
Concept
Theoretically, Interim Analysis is a planned statistical evaluation of accumulating clinical trial data conducted before completion of the study. It is based on sequential statistical inference and allows predefined decisions regarding efficacy, futility or safety while preserving the scientific validity and integrity of the trial. In health economics, interim analyses improve the efficiency of clinical evidence generation and may accelerate the availability of treatment effectiveness data used in health technology assessment and economic evaluation.
Mathematically, interim analysis applies sequential hypothesis testing using pre-specified stopping boundaries that control the overall Type I error rate across multiple analyses. Test statistics are compared with efficacy or futility boundaries derived from alpha-spending functions or group sequential methods. Bayesian interim analyses instead evaluate posterior or predictive probabilities to guide trial decisions.
In practice, interim analyses are scheduled within the trial protocol before recruitment begins and are conducted by an independent Data Safety Monitoring Board using unblinded data. Depending on the statistical results, the trial may continue unchanged, stop early for efficacy, stop for futility or be modified according to a pre-specified adaptive design. The resulting evidence subsequently informs health economic models and reimbursement decisions.
Purpose
Used to evaluate accumulating clinical trial evidence before study completion, enabling predefined decisions regarding efficacy, safety or futility while maintaining statistical validity and improving the efficiency of evidence generation.
Mathematical Formulae
Primary Formula
Z? � c?
where Z? is the interim test statistic and c? is the pre-specified stopping boundary.
Supporting Formulae
Information Fraction:
t? = I? / Imax
Overall Type I Error:
� = ?�?
Conditional Power:
CP = P(Reject H? at final analysis � Interim data)
Related Mathematical Methods
- Group sequential design
- Alpha-spending functions
- O'Brien?Fleming boundaries
- Pocock boundaries
- Conditional power
- Bayesian adaptive design
- Futility analysis
Example
A phase III cardiovascular trial plans interim analyses after 50% and 75% of the required events have occurred. At the first interim analysis, the observed Z statistic exceeds the pre-specified efficacy boundary. Following review by the independent Data Safety Monitoring Board, the trial is stopped early because sufficient evidence of treatment benefit has been demonstrated. These results are subsequently incorporated into a cost-effectiveness analysis.
Excel Implementation
| Function | Example Formula | Health Economics Application |
|---|---|---|
| NORM.S.DIST | =NORM.S.DIST(ZScore,TRUE) | Calculates cumulative probabilities for interim monitoring. |
| NORM.S.INV | =NORM.S.INV(1-Alpha/2) | Calculates critical stopping boundaries. |
| IF | =IF(ZScore>=Boundary,"Stop","Continue") | Applies interim decision rules. |
| SUMPRODUCT | =SUMPRODUCT(Probabilities,Outcomes) | Calculates expected treatment outcomes during interim evaluation. |
VBA (Optional)
Automate interim statistical analyses, evaluate predefined stopping rules and generate monitoring reports for Data Safety Monitoring Board review.
Sources
- Jennison C, Turnbull BW. Group Sequential Methods with Applications to Clinical Trials.
- O'Brien PC, Fleming TR. A Multiple Testing Procedure for Clinical Trials.
- Pocock SJ. Group Sequential Methods in the Design and Analysis of Clinical Trials.
- FDA. Adaptive Designs for Clinical Trials of Drugs and Biologics: Guidance for Industry.
- EMA. Reflection Paper on Methodological Issues in Confirmatory Clinical Trials Planned with an Adaptive Design.
- Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation.
Related Concepts (2)
Library
Publications
1
Economic Evaluation in Clinical Trials — Glick, Doshi, Sonnad & Polsky, 2nd Edition ed., 2015 (Oxford University Press)
Practical guidance on conducting cost-effectiveness analyses alongside controlled trials, covering trial design, measurement of costs and quality-adjusted life years, handling censored and missing data, and reporting stochastic uncertainty. Volume 4 in the Handbooks in Health Economic Evaluation series.
BookView source →
Frequently Asked Questions (6)
What is an interim analysis?
A planned analysis of trial data conducted before final completion, typically to assess safety, efficacy, or futility and inform continuation decisions.
Source: Pocock 1977
Why does looking at trial data early risk a false positive?
Each time accumulating trial data are tested against a threshold for significance, there is a fresh chance of a false positive, so testing repeatedly at interim points inflates the overall risk of wrongly declaring an effect. To guard against this, interim analyses use stricter significance thresholds at each look, spending the allowable error sparingly so that the total risk across all analyses stays controlled. Without such adjustment, an early peek could produce a spurious result. Repeated looks demand a stricter bar. Jennison and Turnbull (2000) describe this.
Source: Jennison & Turnbull 2000
Why are interim analyses conducted?
Interim analyses are conducted to monitor a trial's accumulating data so that it can be stopped or modified early when warranted: to protect participants if a treatment is causing harm, to allow early adoption if benefit is clearly demonstrated, and to avoid wasting resources if the trial is unlikely to succeed. They also check trial conduct and assumptions. By enabling timely decisions based on emerging evidence, interim analyses make trials more ethical and efficient, provided they are planned in advance with methods that preserve the trial's statistical validity despite the repeated examination of the data.
Source: Pocock 1977
How is statistical error controlled in interim analyses?
Statistical error is controlled in interim analyses by pre-specifying the number and timing of the analyses and using methods, such as group-sequential stopping boundaries, that adjust the significance thresholds so that the overall probability of a false-positive result remains at the intended level despite the multiple looks. Without such adjustment, repeatedly testing the data would inflate the chance of a spurious significant result. The boundaries are more stringent at earlier analyses. By planning the interim analyses and applying appropriate methods, the trial preserves its error rates while allowing early stopping.
Source: Pocock 1977
Who conducts and reviews interim analyses?
Interim analyses are typically conducted and reviewed with the involvement of an independent data safety monitoring board, which examines the unblinded accumulating data and makes recommendations about continuing, modifying, or stopping the trial, keeping the investigators blinded to preserve the trial's integrity. Independent review is important, since seeing interim results could bias those running the trial. The board weighs the evidence against participant safety and the value of completing the trial. So interim analyses are handled through independent oversight to protect both participants and the validity of the trial.
Source: Friedman, Furberg & DeMets 2015
What are the risks of interim analyses?
The risks of interim analyses include inflating the false-positive rate if the multiple looks are not accounted for statistically; stopping a trial early on limited data that could give a misleading result, such as overestimating an effect; and compromising trial integrity if interim results become known to investigators and influence conduct. Early stopping also reduces the data available for secondary questions. These risks mean interim analyses are pre-planned with appropriate error control, conducted under independent oversight with blinding preserved, and their results, especially from early stopping, interpreted with caution.
Source: Pocock 1977
Trust Record
Verified by Dr Darrin Baines
British health economist
Professional identity: darrinbaines.org
Verification date: 14 Nov 2025
Content version: 1.0.0
Canonical Identity
- Persistent URI
- https://healtheconomics.wiki/concept/interim-analysis
- Term code
- HE-ES-CTM-047
Stable URI · Machine-readable · Resolvable · CC BY 4.0